Characteristics of oncology clinical trials

Insights from a systematic analysis of clinicaltrials.gov

Bradford R. Hirsch, Robert M. Califf, Steven K. Cheng, Asba Tasneem, John Horton, Karen Chiswell, Kevin A. Schulman, David Dilts, Amy P. Abernethy

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Importance: Clinical trials are essential to cancer care, and data about the current state of research in oncology are needed to develop benchmarks and set the stage for improvement. Objective: To perform a comprehensive analysis of the national oncology clinical research portfolio. Design: All interventional clinical studies registered on ClinicalTrials.gov between October 2007 and September 2010 were identified using Medical Subject Heading terms and submitted conditions. They were reviewed to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. Results: Of 40 970 interventional studies registered between October 2007 and September 2010, a total of 8942 (21.8%) focused on oncology. Compared with other specialties, oncology trials were more likely to be single arm (62.3% vs 23.8%; P <.001), open label (87.8% vs 47.3%; P <.001), and nonrandomized (63.9% vs 22.7%; P <.001). There was moderate but significant correlation between number of trials conducted by cancer type and associated incidence and mortality (Spearman rank correlation coefficient, 0.56 [P =.04] and 0.77 [P =.001], respectively). More than one-third of all oncology trials were conducted solely outside North America. Conclusions and Relevance : There are significant variations between clinical trials in oncology and other diseases, as well as among trials within oncology. The differences must be better understood to improve both the impact of cancer research on clinical practice and the use of constrained resources.

Original languageEnglish (US)
Pages (from-to)972-979
Number of pages8
JournalJAMA Internal Medicine
Volume173
Issue number11
DOIs
StatePublished - Jun 10 2013

Fingerprint

Clinical Trials
Neoplasms
Research
Medical Subject Headings
Benchmarking
Medical Oncology
Nonparametric Statistics
North America
Mortality
Incidence

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hirsch, B. R., Califf, R. M., Cheng, S. K., Tasneem, A., Horton, J., Chiswell, K., ... Abernethy, A. P. (2013). Characteristics of oncology clinical trials: Insights from a systematic analysis of clinicaltrials.gov. JAMA Internal Medicine, 173(11), 972-979. https://doi.org/10.1001/jamainternmed.2013.627

Characteristics of oncology clinical trials : Insights from a systematic analysis of clinicaltrials.gov. / Hirsch, Bradford R.; Califf, Robert M.; Cheng, Steven K.; Tasneem, Asba; Horton, John; Chiswell, Karen; Schulman, Kevin A.; Dilts, David; Abernethy, Amy P.

In: JAMA Internal Medicine, Vol. 173, No. 11, 10.06.2013, p. 972-979.

Research output: Contribution to journalArticle

Hirsch, BR, Califf, RM, Cheng, SK, Tasneem, A, Horton, J, Chiswell, K, Schulman, KA, Dilts, D & Abernethy, AP 2013, 'Characteristics of oncology clinical trials: Insights from a systematic analysis of clinicaltrials.gov', JAMA Internal Medicine, vol. 173, no. 11, pp. 972-979. https://doi.org/10.1001/jamainternmed.2013.627
Hirsch, Bradford R. ; Califf, Robert M. ; Cheng, Steven K. ; Tasneem, Asba ; Horton, John ; Chiswell, Karen ; Schulman, Kevin A. ; Dilts, David ; Abernethy, Amy P. / Characteristics of oncology clinical trials : Insights from a systematic analysis of clinicaltrials.gov. In: JAMA Internal Medicine. 2013 ; Vol. 173, No. 11. pp. 972-979.
@article{28282c4bf96e481883a2c4d2414768d9,
title = "Characteristics of oncology clinical trials: Insights from a systematic analysis of clinicaltrials.gov",
abstract = "Importance: Clinical trials are essential to cancer care, and data about the current state of research in oncology are needed to develop benchmarks and set the stage for improvement. Objective: To perform a comprehensive analysis of the national oncology clinical research portfolio. Design: All interventional clinical studies registered on ClinicalTrials.gov between October 2007 and September 2010 were identified using Medical Subject Heading terms and submitted conditions. They were reviewed to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. Results: Of 40 970 interventional studies registered between October 2007 and September 2010, a total of 8942 (21.8{\%}) focused on oncology. Compared with other specialties, oncology trials were more likely to be single arm (62.3{\%} vs 23.8{\%}; P <.001), open label (87.8{\%} vs 47.3{\%}; P <.001), and nonrandomized (63.9{\%} vs 22.7{\%}; P <.001). There was moderate but significant correlation between number of trials conducted by cancer type and associated incidence and mortality (Spearman rank correlation coefficient, 0.56 [P =.04] and 0.77 [P =.001], respectively). More than one-third of all oncology trials were conducted solely outside North America. Conclusions and Relevance : There are significant variations between clinical trials in oncology and other diseases, as well as among trials within oncology. The differences must be better understood to improve both the impact of cancer research on clinical practice and the use of constrained resources.",
author = "Hirsch, {Bradford R.} and Califf, {Robert M.} and Cheng, {Steven K.} and Asba Tasneem and John Horton and Karen Chiswell and Schulman, {Kevin A.} and David Dilts and Abernethy, {Amy P.}",
year = "2013",
month = "6",
day = "10",
doi = "10.1001/jamainternmed.2013.627",
language = "English (US)",
volume = "173",
pages = "972--979",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Characteristics of oncology clinical trials

T2 - Insights from a systematic analysis of clinicaltrials.gov

AU - Hirsch, Bradford R.

AU - Califf, Robert M.

AU - Cheng, Steven K.

AU - Tasneem, Asba

AU - Horton, John

AU - Chiswell, Karen

AU - Schulman, Kevin A.

AU - Dilts, David

AU - Abernethy, Amy P.

PY - 2013/6/10

Y1 - 2013/6/10

N2 - Importance: Clinical trials are essential to cancer care, and data about the current state of research in oncology are needed to develop benchmarks and set the stage for improvement. Objective: To perform a comprehensive analysis of the national oncology clinical research portfolio. Design: All interventional clinical studies registered on ClinicalTrials.gov between October 2007 and September 2010 were identified using Medical Subject Heading terms and submitted conditions. They were reviewed to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. Results: Of 40 970 interventional studies registered between October 2007 and September 2010, a total of 8942 (21.8%) focused on oncology. Compared with other specialties, oncology trials were more likely to be single arm (62.3% vs 23.8%; P <.001), open label (87.8% vs 47.3%; P <.001), and nonrandomized (63.9% vs 22.7%; P <.001). There was moderate but significant correlation between number of trials conducted by cancer type and associated incidence and mortality (Spearman rank correlation coefficient, 0.56 [P =.04] and 0.77 [P =.001], respectively). More than one-third of all oncology trials were conducted solely outside North America. Conclusions and Relevance : There are significant variations between clinical trials in oncology and other diseases, as well as among trials within oncology. The differences must be better understood to improve both the impact of cancer research on clinical practice and the use of constrained resources.

AB - Importance: Clinical trials are essential to cancer care, and data about the current state of research in oncology are needed to develop benchmarks and set the stage for improvement. Objective: To perform a comprehensive analysis of the national oncology clinical research portfolio. Design: All interventional clinical studies registered on ClinicalTrials.gov between October 2007 and September 2010 were identified using Medical Subject Heading terms and submitted conditions. They were reviewed to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. Results: Of 40 970 interventional studies registered between October 2007 and September 2010, a total of 8942 (21.8%) focused on oncology. Compared with other specialties, oncology trials were more likely to be single arm (62.3% vs 23.8%; P <.001), open label (87.8% vs 47.3%; P <.001), and nonrandomized (63.9% vs 22.7%; P <.001). There was moderate but significant correlation between number of trials conducted by cancer type and associated incidence and mortality (Spearman rank correlation coefficient, 0.56 [P =.04] and 0.77 [P =.001], respectively). More than one-third of all oncology trials were conducted solely outside North America. Conclusions and Relevance : There are significant variations between clinical trials in oncology and other diseases, as well as among trials within oncology. The differences must be better understood to improve both the impact of cancer research on clinical practice and the use of constrained resources.

UR - http://www.scopus.com/inward/record.url?scp=84878802996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878802996&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2013.627

DO - 10.1001/jamainternmed.2013.627

M3 - Article

VL - 173

SP - 972

EP - 979

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 11

ER -